Affimed's (AFMD) "Overweight" Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Affimed (NASDAQ:AFMD - Free Report) in a research report sent to investors on Tuesday,Benzinga reports.

Several other analysts have also commented on the stock. HC Wainwright restated a "buy" rating and set a $10.00 price target on shares of Affimed in a research report on Friday. Stifel Nicolaus dropped their price target on shares of Affimed from $5.00 to $4.00 and set a "hold" rating on the stock in a research report on Friday. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $16.00.

Affimed Stock Down 5.1 %

Shares of Affimed stock traded down $0.16 during trading on Tuesday, hitting $3.00. 238,546 shares of the company's stock were exchanged, compared to its average volume of 266,242. The company has a current ratio of 1.93, a quick ratio of 1.93 and a debt-to-equity ratio of 0.13. The business has a 50-day simple moving average of $3.45 and a 200-day simple moving average of $4.48. Affimed has a 52-week low of $2.90 and a 52-week high of $8.95.

Affimed (NASDAQ:AFMD - Get Free Report) last released its quarterly earnings results on Thursday, September 5th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($1.00) by ($0.09). The firm had revenue of $0.17 million for the quarter, compared to analyst estimates of $1.67 million. Affimed had a negative net margin of 7,836.26% and a negative return on equity of 193.84%. As a group, equities research analysts forecast that Affimed will post -4.25 earnings per share for the current year.

Institutional Trading of Affimed

Several institutional investors have recently modified their holdings of the stock. Point72 Asset Management L.P. grew its position in shares of Affimed by 4.6% in the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company's stock valued at $1,152,000 after purchasing an additional 15,108 shares during the period. Intellectus Partners LLC grew its position in shares of Affimed by 12.2% in the third quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company's stock valued at $317,000 after purchasing an additional 10,250 shares during the period. FMR LLC grew its position in shares of Affimed by 30.0% in the third quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company's stock valued at $59,000 after purchasing an additional 4,086 shares during the period. Jane Street Group LLC acquired a new stake in shares of Affimed in the third quarter valued at about $44,000. Finally, Choreo LLC acquired a new stake in shares of Affimed in the second quarter valued at about $54,000. Institutional investors and hedge funds own 30.82% of the company's stock.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.